Shares of Eli Lilly and Company (NYSE:LLY) have been assigned a consensus recommendation of “Hold” from the twenty-three ratings firms that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $88.44.

A number of equities research analysts have recently commented on LLY shares. BMO Capital Markets downgraded Eli Lilly and from a “market perform” rating to an “underperform” rating and cut their price objective for the company from $73.00 to $71.00 in a research report on Monday, April 17th. Morgan Stanley downgraded Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price objective for the company. in a research report on Monday, April 17th. Cowen and Company increased their price objective on Eli Lilly and from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Monday, April 17th. Piper Jaffray Companies reiterated a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research report on Monday, April 17th. Finally, Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Tuesday, April 18th.

In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total transaction of $17,730,300.00. Following the transaction, the insider now directly owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock worth $55,845,287 over the last three months. Company insiders own 0.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in Eli Lilly and by 91.1% in the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after buying an additional 2,714,505 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in Eli Lilly and by 24.8% in the second quarter. Parametric Portfolio Associates LLC now owns 2,055,983 shares of the company’s stock valued at $169,207,000 after buying an additional 408,241 shares during the last quarter. Advisor Group Inc. increased its position in Eli Lilly and by 10.9% in the second quarter. Advisor Group Inc. now owns 74,888 shares of the company’s stock valued at $6,028,000 after buying an additional 7,340 shares during the last quarter. Cibc World Markets Corp increased its position in Eli Lilly and by 360.9% in the second quarter. Cibc World Markets Corp now owns 467,359 shares of the company’s stock valued at $38,464,000 after buying an additional 365,967 shares during the last quarter. Finally, Suntrust Banks Inc. increased its position in Eli Lilly and by 0.9% in the second quarter. Suntrust Banks Inc. now owns 183,787 shares of the company’s stock valued at $15,123,000 after buying an additional 1,595 shares during the last quarter. 75.61% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/11/eli-lilly-and-company-nyselly-receives-average-recommendation-of-hold-from-analysts.html.

Eli Lilly and (NYSE LLY) traded down 0.47% during trading on Friday, hitting $81.15. The stock had a trading volume of 2,445,500 shares. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $86.72. The firm’s 50-day moving average price is $83.00 and its 200-day moving average price is $81.69. The stock has a market cap of $85.61 billion, a PE ratio of 35.11 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the firm earned $0.86 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts predict that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.56%. Eli Lilly and’s dividend payout ratio is 90.04%.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.